Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.48 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28823606 | 0.89 | HTR2A (0.50) | HTR2AFFAR4DHFRPKMNPSR1 | |
| SCHEMBL17449704 | 0.86 | HTR2A (0.50) | HTR2AFFAR4DHFRPKMNPSR1 | |
| SCHEMBL16483443 | 0.85 | HTR2A (0.52) | HTR2AFFAR4DHFRPKMNPSR1 | |
| SCHEMBL2439246 | 0.85 | HTR2A (0.52) | HTR2AFFAR4DHFRPKMNPSR1 | |
| SCHEMBL12035510 | 0.84 | FFAR4 (0.54) | HTR2AFFAR4DHFRPKMNPSR1 | |
| SCHEMBL1005341 | 0.81 | HTR2A (0.51) | HTR2AFFAR4DHFRPKMNPSR1 | |
| SCHEMBL18649399 | 0.81 | FFAR4 (0.55) | HTR2AFFAR4DHFRPKMNPSR1 | |
| SCHEMBL2436924 | 0.81 | FFAR4 (0.52) | HTR2AFFAR4DHFRPKMNPSR1 | |
| SCHEMBL2431605 | 0.81 | FFAR4 (0.52) | HTR2AFFAR4DHFRPKMNPSR1 | |
| SCHEMBL17523375 | 0.78 | FFAR4 (0.52) | HTR2AFFAR4DHFRPKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970172-B1 | BICYCLO [2.2.2]ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-2970172-B1 | BICYCLO [2.2.2]ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-30 | — | — | EP | disclosed |
| US-9598390-B2 | Bicyclo[2.2.2]acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598390-B2 | Bicyclo[2.2.2]acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598390-B2 | Bicyclo[2.2.2]acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160039780-A1 | BICYCLO [2.2.2] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160039780-A1 | BICYCLO [2.2.2] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160039780-A1 | BICYCLO [2.2.2] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-11 | — | — | US | disclosed |
| EP-2970172-A1 | BICYCLO [2.2.2]ACID GPR120 MODULATORS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014159802-A1 | BICYCLO [2.2.2] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159802-A1 | BICYCLO [2.2.2] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039780-A1 | BICYCLO [2.2.2] ACID GPR120 MODULATORS | GPR180, GPR88, GPBAR1 | HTR2A 287/4885FFAR4 45/4885DHFR 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.